HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations

Kong, Leopold; Wilson, Ian A.; De Val, Natalia; Ward, Andrew B.; Burton, Dennis R.; He, Linling; Zhu, Jiang

Title: HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations

Abstract

The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.

Inventors:: Kong, Leopold; Wilson, Ian A.; De Val, Natalia; Ward, Andrew B.; Burton, Dennis R.; He, Linling; Zhu, Jiang

Issue Date:: 2020-05-12

Research Org.:: Argonne National Laboratory (ANL), Argonne, IL (United States)

Sponsoring Org.:: USDOE

OSTI Identifier:: 1650887

Patent Number(s):: 10647748

Application Number:: 16/176,200

Assignee:: The Scripps Research Institute (La Jolla, CA)

Patent Classifications (CPCs):: A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

Show more

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
A61K2039/5258 - {Virus-like particles}
A61K2039/6031 - {Proteins}
A61K2039/645 - {Dendrimers
A61K39/12 - Viral antigens
A61K39/21 - Retroviridae, e.g. equine infectious anemia virus
A61K47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K47/6929 - {the form being a nanoparticle, e.g. an immuno-nanoparticle}

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P31/18 - for HIV
A61P37/04 - Immunostimulants

C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07K - PEPTIDES
C07K14/005 - from viruses
C07K14/162 - {env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site}
C07K2319/735 - containing a domain for self-assembly, e.g. a viral coat protein

C - CHEMISTRY C12 - BIOCHEMISTRY C12N - MICROORGANISMS OR ENZYMES
C12N2740/16122 - New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16134 - Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N7/02 - Recovery or purification

Show less

DOE Contract Number:: AC02-06CH11357

Resource Type:: Patent

Resource Relation:: Patent File Date: 10/31/2018

Country of Publication:: United States

Language:: English

Subject:: 59 BASIC BIOLOGICAL SCIENCES

Citation Formats


                    Kong, Leopold, Wilson, Ian A., De Val, Natalia, Ward, Andrew B., Burton, Dennis R., He, Linling, and Zhu, Jiang. HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations.  United States: N. p., 2020. 
        Web.

Copy to clipboard


                    Kong, Leopold, Wilson, Ian A., De Val, Natalia, Ward, Andrew B., Burton, Dennis R., He, Linling, & Zhu, Jiang. HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations.  United States.

Copy to clipboard


                    Kong, Leopold, Wilson, Ian A., De Val, Natalia, Ward, Andrew B., Burton, Dennis R., He, Linling, and Zhu, Jiang. Tue .  
        "HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations".  United States.  https://www.osti.gov/servlets/purl/1650887.

Copy to clipboard


                    
@article{osti_1650887,

  title        = {HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations},

  author       = {Kong, Leopold and Wilson, Ian A. and De Val, Natalia and Ward, Andrew B. and Burton, Dennis R. and He, Linling and Zhu, Jiang},

  abstractNote = {The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.},

  doi          = {},

  journal      = {},
number       = ,

  volume       = ,

  place        = {United States},

  year         = {2020},

  month        = {5}

}

Copy to clipboard

Patent:

Save / Share:

Export Metadata

Save to My Library

Works referenced in this record:

Novel HIV-1 Envelope Glycoprotein
patent-application, July 2014

Caulfield, Michael; Cupo, Albert; Dean, HAnsi
US Patent Application 14/072209; 20140212458
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20140212458

Similar Records in DOE Patents and OSTI.GOV collections:

Nucleic acids encoding HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations

Patent Kong, Leopold; Wilson, Ian A.; De Val, Natalia; ...

The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
Full Text Available
Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins

Patent Korber, Bette T [Los Alamos, NM]; Perkins, Simon [Los Alamos, NM]; Bhattacharya, Tanmoy [Los Alamos, NM]; ...

The present invention relates to mosaic clade M HIV-1 Nef polypeptides and to compositions comprising same. The polypeptides of the invention are suitable for use in inducing an immune response to HIV-1 in a human.
Full Text Available
Nucleic acids encoding mosaic conserved region HIV immunogenic polypeptides

Patent Korber, Bette T. M.; Hanke, Tomas; McMichael, Andrew

Disclosed herein are mosaic conserved region HIV polypeptides and immunogenic polypeptides including one or more of the mosaic conserved region polypeptides. In some embodiments, the immunogenic polypeptides are included in an immunogenic composition, such as a polyvalent immunogenic composition. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject having or at risk of HIV infection. In some embodiments, the methods include inducing an immune response in a subject comprising administering to the subject at least one of the disclosed immunogenic polypeptidesmore » « less
Full Text Available
Mosaic conserved region HIV immunogenic polypeptides

Patent Korber, Bette T. M.; Hanke, Tomas; McMichael, Andrew

Disclosed herein are mosaic conserved region HIV polypeptides and immunogenic polypeptides including one or more of the mosaic conserved region polypeptides. In some embodiments, the immunogenic polypeptides are included in an immunogenic composition, such as a polyvalent immunogenic composition. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject having or at risk of HIV infection. In some embodiments, the methods include inducing an immune response in a subject comprising administering to the subject at least one of the disclosed immunogenic polypeptidesmore » « less
Full Text Available
Nucleic acids encoding mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens

Patent Korber, Bette T; Fischer, William; Liao, Hua-Xin; ...

The present invention relates to nucleic acids encoding mosaic clade M HIV-1 Env polypeptides and to compositions and vectors comprising same. The nucleic acids of the invention are suitable for use in inducing an immune response to HIV-1 in a human.
Full Text Available

Similar Records

Title: HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations

Abstract

Citation Formats

Novel HIV-1 Envelope Glycoprotein patent-application, July 2014

Novel HIV-1 Envelope Glycoprotein
patent-application, July 2014